The ALS Association recently announced that it has awarded an ALS Association-Initiated Grant to researchers at Origent Data Sciences Inc. and Cytokinetics Inc., in order to develop a research partnership between the two companies.
The goal is to refine and confirm that a model generated with an Origent computer can predict the progression of ALS disease. This is possible with data taken from the tirasemtiv clinical trials conducted at Cytokinetics.
“We are extremely excited to see this collaboration get underway,” Lucie Bruijn, ALS Association's chief scientist, said. “This tool has the potential to accelerate clinical trials for ALS, and the Cytokinetics phase-three trial provides an excellent opportunity to validate the disease progression algorithm.”
The grant, which amounts to $497,433, will be used to improve the partners’ clinical trial design, titled “Prospective Validation of ALS Disease Models and Tools.”
“This unique collaboration between Origent Data Sciences, Cytokinetics and The ALS Association reflects another step in our collective efforts to accelerate the clinical trial process and make new medicines available to people with ALS in desperate need of new therapeutic options,” Jinsy Andrews, Cytokinetics’ senior director of clinical research and development, said. “We are pleased to join with Origent to potentially validate their predictive model using datasets from Benefit-ALS and Vitality-ALS, which we hope may then facilitate the use of this novel technology to positively impact the design and conduct of future ALS clinical trials.”